Degradation Pathways of a Corticotropin-Releasing Factor Antagonist in Solution and Solid States

被引:3
|
作者
Badawy, S. [1 ]
Hussain, M. [1 ]
Zhao, F. [1 ]
Ye, Q. [1 ]
Huang, Y. [1 ]
Palaniswamy, V. [1 ]
机构
[1] Bristol Myers Squibb Co, Pharmaceut Dev, New Brunswick, NJ 08903 USA
关键词
chemical stability; stability; solid state stability; stabilization; solid dosage form; HYDROLYSIS;
D O I
10.1002/jps.21637
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Stability of the 1,3,5-triazine derivative (1), a corticotropin-releasing factor inhibitor, was studied in acidic solutions and in solid formulations. Degradant structures were elucidated using liquid chromatography/mass spectrometry (LC/MS) and nuclear magnetic resonance (NMR). Compound I was found to undergo hydrolysis via two pathways. Pathway 1 involves three hydrolysis steps of the triazine ring. Pathway 2 proceeds through hydroxy substitution of the amino group on the triazine ring followed by its hydrolysis, eventually resulting in the formation of the same degradant as pathway 1. Stability of 1 in the tablets was dependent on the manufacturing process and degradation appeared to proceed more rapidly in amorphous regions created during processing. Pathways 1 and 2 were observed in the tablets and degradation rate was enhanced at. high humidity condition. In addition to pathways I and 2, degradation in the tablet formulations was found to proceed through a third pathway involving nucleophilic displacement of the ether methoxy group by the triazine N-3. The resulting imidazolidinium intermediate was found to undergo a series of hydrolytic steps finally leading to the same end degradant as pathways 1 and 2. This intermediate was observed at a lower concentration in the tablet at the high humidity conditions and at very low concentrations in acidic solutions. (C) 2008 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 98:2636-2647, 2009
引用
收藏
页码:2636 / 2647
页数:12
相关论文
共 50 条
  • [21] Intersections of Sex and Corticotropin-Releasing Factor
    Gourley, Shannon L.
    Taylor, Jane R.
    BIOLOGICAL PSYCHIATRY, 2014, 75 (11) : 838 - 839
  • [22] SERIOUS REACTIONS TO CORTICOTROPIN-RELEASING FACTOR
    HERMUS, A
    RAEMAEKERS, JMM
    PIETERS, GFFM
    BARTELINK, AKM
    SMALS, AGH
    KLOPPENBORG, PWC
    LANCET, 1983, 1 (8327): : 776 - 776
  • [23] CORTICOTROPIN-RELEASING FACTOR STIMULATION TEST
    ELIAS, AN
    GWINUP, G
    NEW ENGLAND JOURNAL OF MEDICINE, 1984, 311 (07): : 471 - 472
  • [24] Corticotropin-releasing factor receptors: An overview
    Dieterich, KD
    Lehnert, H
    DeSouza, EB
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 1997, 105 (02) : 65 - 82
  • [25] PHYSIOLOGY AND PHARMACOLOGY OF CORTICOTROPIN-RELEASING FACTOR
    OWENS, MJ
    NEMEROFF, CB
    PHARMACOLOGICAL REVIEWS, 1991, 43 (04) : 425 - 473
  • [26] The Contribution of Corticotropin-Releasing Factor to Gastroprotection
    L. P. Filaretova
    Neurochemical Journal, 2018, 12 : 127 - 129
  • [27] CONFORMATIONAL STUDIES ON THE CORTICOTROPIN-RELEASING FACTOR
    BODE, K
    MABILIA, M
    PALLAI, P
    GOODMAN, M
    RIVIER, J
    BIOPHYSICAL JOURNAL, 1983, 41 (02) : A393 - A393
  • [28] Heterogeneity of corticotropin-releasing factor (CRF)
    Yasuda, N
    Nakamura, K
    JAPANESE JOURNAL OF PHYSIOLOGY, 1997, 47 (02): : 147 - 159
  • [29] Placental corticotropin-releasing factor - An update
    Fadalti, M
    Pezzani, I
    Cobellis, L
    Springolo, F
    Petrovec, MM
    Ambrosini, G
    Reis, FM
    Petraglia, F
    YOUNG WOMAN AT THE RISE OF THE 21ST CENTURY: GYNECOLOGICAL AND REPRODUCTIVE ISSUES IN HEALTH AND DISEASE, 2000, 900 : 89 - 94
  • [30] CORTICOTROPIN-RELEASING FACTOR CHARACTERIZED AND SYNTHESIZED
    不详
    HOSPITAL PRACTICE, 1981, 16 (11): : 145 - &